Care of the Patient with a Sleep Disorder

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Download Full-text

The Stony Brook 600 the Experience of a Sleep Disorder Center

Annals of Clinical Psychiatry ◽

10.3109/10401239009147957 ◽

1990 ◽

Vol 2 (4) ◽

pp. 277-283 ◽

Cited By ~ 3

Author(s):

Wallace Mendelson

Keyword(s):

Sleep Disorder

Download Full-text

Relationship between Sleep and Hypertension: Findings from the NHANES (2007–2014)

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18157867 ◽

2021 ◽

Vol 18 (15) ◽

pp. 7867

Author(s):

Chunnan Li ◽

Shaomei Shang

Keyword(s):

Blood Pressure ◽

Sleep Disorder ◽

Sleep Duration ◽

Sleep Pattern ◽

Poor Sleep ◽

Sleep Patterns ◽

Short Sleep Duration ◽

Logistic Regression Models ◽

Increased Risk ◽

Definition Of

Background: To evaluate the association of sleep factors (sleep duration, self-reported trouble sleeping, diagnosed sleep disorder) and combined sleep behaviors with the risk of hypertension. Methods: We analyzed 12,166 adults aged 30–79 years who participated in the 2007–2014 National Health and Nutrition Examination Survey. Sleep duration, self-reported trouble sleeping and sleep disorders were collected using a standardized questionnaire. We included three sleep factors (sleep duration, self-reported trouble sleeping and sleep disorder) to generate an overall sleep score, ranging from 0 to 3. We then defined the sleep pattern as “healthy sleep pattern” (overall sleep score = 3), “intermediate sleep pattern” (overall sleep score = 2), and “poor sleep pattern” (0 ≤ overall sleep score ≤ 1) based on the overall sleep score. The definition of hypertension was based on self-reported antihypertensive medication use or biological measurement (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg). We used weighted logistic regression models to investigate the associations between sleep and hypertension. Results: The overall prevalence of hypertension was 37.8%. A short sleep duration (OR = 1.20, 95% CI: 1.08 to 1.33, p = 0.001), self-reported trouble sleeping (OR = 1.45, 95% CI: 1.28 to 1.65, p < 0.001) and sleep disorder (OR = 1.33, 95% CI: 1.07 to 1.66, p = 0.012) were related to the risk of hypertension. Poor sleep patterns were closely correlated with the risk of hypertension (OR = 1.90, 95% CI: 1.62 to 2.24). Conclusions: Participants with poor sleep patterns were associated with an increased risk for hypertension.

Download Full-text

Opioid overdose increases with concomitant sleep disorder therapy

Reactions Weekly ◽

10.1007/s40278-021-95340-0 ◽

2021 ◽

Vol 1854 (1) ◽

pp. 9-9

Keyword(s):

Sleep Disorder ◽

Opioid Overdose

Download Full-text

Comorbid Insomnia and Sleep Apnea: mechanisms and implications of an underrecognized and misinterpreted sleep disorder

Sleep Medicine ◽

10.1016/j.sleep.2021.05.043 ◽

2021 ◽

Author(s):

Miguel Meira e Cruz ◽

Meir Kryger ◽

Charles Morin ◽

Luciana Palombini ◽

Cristina Salles ◽

...

Keyword(s):

Sleep Apnea ◽

Sleep Disorder ◽

Comorbid Insomnia

Download Full-text

Improvement in mild anti-IgLON5 encephalopathy without immunotherapy: a case report

BMC Neurology ◽

10.1186/s12883-021-02145-4 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yuting Wang ◽

Xiuling Wu ◽

Baoquan Lu

Keyword(s):

Sleep Disorder ◽

Clinical Symptoms ◽

Antiviral Treatment ◽

Primary Treatment ◽

Serum Analysis ◽

Autonomic Nervous System Dysfunction ◽

Case Presentation ◽

Mild Disease ◽

Prominent Symptom ◽

Vertical Gaze

Abstract Background Anti-IgLON5 antibody-related encephalopathy is a recently discovered and rare autoimmune disease, and its diagnosis and treatment are more challenging than for other autoimmune encephalopathic diseases. Sleep disorder is the most prominent symptom of the disease. It can also present with gait instability, dysarthria, dysphagia, dementia, ataxia, autonomic nervous system dysfunction, chorea, vertical gaze paralysis, and other symptoms. Immunotherapy remains the primary treatment for this disease; however, there is no definitive conclusion regarding the effect of immunotherapy. The clinical symptoms of the reported cases of anti-IgLON5 antibody-related encephalopathy were generally severe. However, the symptoms in our patient were mild and relieved without immunotherapy, unlike the previously reported cases. Case presentation A 62-year-old man presented with behavioural abnormalities and involuntary movements after nearly 2 months of fever and headache. He also had symptoms of mild sleep disorder. Due to the abnormal levels of infection-related indicators, antiviral treatment was started on the day of admission. The serum analysis confirmed the presence of IgLON5 antibody, and the patient was found to be genetically susceptible. The patient’s symptoms resolved rapidly without immunotherapy and did not recur. Conclusions This case demonstrated that IgLON5 antibody-related encephalopathy might have mild manifestations. Infection and a genetic predisposition may be important causes for the disease. Patients with a mild disease may have a better prognosis.

Download Full-text